Northwest Biotherapeutics, Inc Stock OTC Bulletin Board
Equities
US66737P5017
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-10 | Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-21 | Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors | CI |
Sales 2022 | 1.68M 2.3M | Sales 2023 | 1.93M 2.64M | Capitalization | 822M 1.12B |
---|---|---|---|---|---|
Net income 2022 | -105M -143M | Net income 2023 | -62M -84.61M | EV / Sales 2022 | 505 x |
Net Debt 2022 | 19.29M 26.32M | Net Debt 2023 | 43.43M 59.27M | EV / Sales 2023 | 448 x |
P/E ratio 2022 |
-7.59
x | P/E ratio 2023 |
-11.7
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 90.82% |
Managers | Title | Age | Since |
---|---|---|---|
Linda Powers
CEO | Chief Executive Officer | 68 | 07-05-16 |
Alton Boynton
FOU | Founder | 79 | 96-03-17 |
Marnix Bosch
CTO | Chief Tech/Sci/R&D Officer | 65 | 99-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alton Boynton
FOU | Founder | 79 | 96-03-17 |
Linda Powers
CEO | Chief Executive Officer | 68 | 07-05-16 |
Navid Malik
BRD | Director/Board Member | 55 | 12-03-31 |
1st Jan change | Capi. | |
---|---|---|
+14.16% | 118B | |
+12.89% | 106B | |
-3.75% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.29% | 15.56B | |
+4.22% | 13.63B | |
+27.42% | 12.27B |